agent-797
agent-797: developed by 1 company · 3 clinical trials tracked.
agent-797 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
How could agent-797 → INKT affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| MiNK Therapeutics, Inc. (INKT) Respiratory Distress Syndrome, Adult; Pneumonia | Phase 1 |
Clinical Trials (3)
Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria
Primary endpoint: Number of Deaths (All-cause Mortality)
Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome
Primary endpoint: 28-day all-cause mortality
A Phase 1 Study of agenT-797 to Treat Moderate to Severe Acute Respiratory Syndrome in COVID-19 Patients
Primary endpoint: Number of Participants with Treatment-emergent Adverse Events
Frequently asked questions
Who is developing agent-797?
agent-797 is being developed by MiNK Therapeutics, Inc..
How many clinical trials involve agent-797?
BioSniper tracks 3 clinical trials involving agent-797.